EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients

Denise Kelley iD, Sarah Piccuirro iD, Prakruti Gandhi, Hannah Kim

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025

DOI: 10.1002/phar.70080 ↗

At a glance

Multizentrische Studie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Written by Denise Kelley and 3 co-authors. Institution: University of Texas College of Pharmacy, Austin, Texas, USA. Major MEDLINE topics: Hyperkalemia, Overweight, Insulin, Hypoglycemic Agents. 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Intravenous regular insulin is often used for the management of hyperkalemia due to its rapid onset of action and predictable potassium‐lowering effects. Various studies have been conducted to determine optimal insulin dosing strategies that reduce serum potassium levels without increasing hypoglycemia risk. As data shifts towards lower or fixed insulin doses, validating the appropriateness of these dosing regimens for the management of hyperkalemia in overweight patients is warranted. The purpose of this study was to evaluate the serum potassium‐lowering effects of 5 units versus 10 units of intravenous regular insulin in hyperkalemic patients with a body mass index (BMI) ≥ 25 kg/m 2 .

Methods

A multicenter, retrospective study was performed in adult patients with BMI ≥ 25 kg/m 2 who received 5 or 10 units of intravenous regular insulin for the treatment of hyperkalemia. The primary outcome was the potassium‐lowering effects of 5 units versus 10 units of intravenous regular insulin. Secondary outcomes include the incidence of hypoglycemic episodes within 6 h of insulin administration, hospital length of stay (LOS), and treatment failure.

Results

Of 699 patients screened, 81 patients received 5 units and 81 patients received 10 units. There was no difference in the serum potassium‐lowering effects of 5 units versus 10 units of intravenous regular insulin (0.5 (0.1–1.1) mmol/L vs. 0.5 (0.2–1) mmol/L; p = 0.65). No significant differences were observed for any secondary outcomes. Subgroup analyses revealed no significant differences for BMI; the number of concomitant acute potassium‐lowering therapies received; or the degree of renal impairment, aside from a significantly larger potassium‐lowering effect with 10 units of intravenous regular insulin observed in the subgroup receiving no concomitant acute potassium‐lowering therapies as well as the subgroup with a creatinine clearance of 30–60 mL/min.

Conclusion

In this small, retrospective cohort study, treatment with 5 units of intravenous regular insulin did not compromise the serum potassium‐lowering effect when compared to 10 units in overweight patients with hyperkalemia. Further controlled studies are warranted to confirm these findings.

Subjects

MeSH terms (MEDLINE)

HyperkalemiaOverweightInsulinHypoglycemic AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedPotassiumBody Mass IndexAdministration, IntravenousHypoglycemiaDose-Response Relationship, DrugAdultTreatment OutcomeLength of Stay

Author keywords

emergency medicinehyperkalemiahypoglycemiaobesityregular insulin

Substances

InsulinPotassiumHypoglycemic Agents

Authors and institutions

  • University of Texas College of Pharmacy, Austin, Texas, USA.
  • Department of Pharmacy, Dell Seton Medical Center at the University of Texas at Austin, Austin, Texas, USA.
  • Department of Pharmacy, Ascension Seton Medical Center Austin, Austin, Texas, USA.

ORCID profiles: Denise Kelley, Sarah Piccuirro

Cite

APA

Kelley, D., Piccuirro, S., Gandhi, P., & Kim, H. (2025). Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70080

Vancouver

Kelley D, Piccuirro S, Gandhi P, Kim H. Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70080

BibTeX
@article{Kelley2025,
  author = {Kelley, Denise and Piccuirro, Sarah and Gandhi, Prakruti and Kim, Hannah},
  title = {Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2025},
  doi = {10.1002/phar.70080}
}
Start for free →